Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

44.95USD
20 Oct 2014
Price Change (% chg)

$0.63 (+1.42%)
Prev Close
$44.32
Open
$44.24
Day's High
$45.03
Day's Low
$44.07
Volume
140,246
Avg. Vol
184,550
52-wk High
$49.10
52-wk Low
$33.05

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.98
Market Cap (Mil.): $93,836.81
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.87

Financials

  NVO.N Industry Sector
P/E (TTM): 26.51 32.64 33.19
EPS (TTM): 1.67 -- --
ROI: 65.79 18.40 17.65
ROE: 71.98 19.06 18.46
Search Stocks

Novo Nordisk's NNIT to announce IPO next week - Berlingske daily

COPENHAGEN, Oct 15 - NNIT, the information technology unit of Danish pharmaceutical company Novo Nordisk , is expected to announce plans for an initial public offering (IPO) on the Nasdaq Copenhagen exchange next week, daily Berlingske reported on Wednesday.

15 Oct 2014

Novo Nordisk's next big idea: a once-weekly insulin shot

COPENHAGEN - Denmark's Novo Nordisk, the world's largest insulin maker, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world's first once-weekly insulin injection.

01 Oct 2014

NORDIC STOCKS - Factors to watch on Sept 19

HELSINKI, Sept 19 - The following stocks may be affected by newspaper reports and other factors on Friday:

19 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment: study

COPENHAGEN - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment -study

COPENHAGEN, Sept 18 - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

NORDIC STOCKS-Factors to watch on Sept 17

COPENHAGEN, Sept 17 - The following stocks may be affected by newspaper reports and other factors on Wednesday:

17 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN, Sept 16 - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

WASHINGTON - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

12 Sep 2014

Executive view: Novo Nordisk to increase its focus on obesity

COPENHAGEN - Novo Nordisk's liraglutide drug is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration (FDA) said on Thursday.

12 Sep 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €80.43 -0.82
Eli Lilly and Co (LLY.N) $63.10 +0.52

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks